Assessing the acute changes between CD4+ T cell naivety and activation serve as attractive areas of further study to better understand not only the contributions of CFTR to Th2 effector identity but also whether CFTR targeting therapies are most viable as a preventative or relief therapy in allergic disease. This evidence concerns the gene CD4 and allergic disease.